Moderate riskFDA DeviceClass II

PTW Freiburg VERIQA RT MonteCarlo 3D v3 software recalled for unclear bolus display in dose calculations

The VERIQA RT MonteCarlo 3D v3 radiation therapy planning software includes bolus (a material placed on the skin to modify radiation dose) in dose calculations, but does not clearly display that the bolus is accounted for. This may cause treatment staff to accidentally skip the bolus during treatment, leading to radiation being delivered to the wrong tissue depth.

From the FDA notice · Read the official notice ↗

What to do

  1. If you use this software version (3.1.18, Model S070031.520), verify that any bolus is visually confirmed before each treatment.
  2. Contact PTW Freiburg or your radiation oncology supervisor for guidance on secondary dose calculations involving bolus.
  3. Check with the manufacturer for a software update or corrective instructions.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Brand Name: VERIQA; Product Name: RT MonteCarlo 3D v3; Model/Catalog Number: S070031.520; Software Version: 3.1.18;
Sold in
Nationwide
Made for
All ages (0 months and older)

Details

Units affected
2
Illnesses reported
None reported
Manufactured in
Lorracher Str. 7, N/A, Freiburg Im Breisgau, N/A, Germany
Classification
Class II
Recall number
Z-3174-2026

In the FDA's words

Description
Brand Name: VERIQA; Product Name: RT MonteCarlo 3D v3; Model/Catalog Number: S070031.520; Software Version: 3.1.18; When a bolus is included in a treatment plan and sent for secondary dose calculation, the software accounts for it but does not display this clearly, which may lead users to incorrectly omit the bolus during treatment and deliver the prescribed dose to the wrong tissue depth. Model/Catalog Number: S070031.520; UDI-DI: +EPTWS070031Q5200; Software Version 3.1.18; Distribution: Worldwide - US Nationwide distribution in the states of GA, NY and the countries of Austria, Belgium, Switzerland, Czechia, Germany, Spain, France, Netherlands, Norway, Poland, Portugal, Romania, T¿rkiye, Chile, United Arab Emirates, Saudi Arabia, Mexico, Hong Kong, Brazil, Tajikistan, Ecuador, Iran, Thailand, Serbia, South Africa, Kazakhstan, Algeria. Affected quantity: 2
Hazard
When a bolus is included in a treatment plan and sent for secondary dose calculation, the software accounts for it but does not display this clearly, which may lead users to incorrectly omit the bolus during treatment and deliver the prescribed dose to the wrong tissue depth.

Related topics

OtherSoftwareMedical devicesSold nationwideMore from FDA Device